Zydus Life’s US revenue may fall 5% in FY26 but Nomura sees a 15% upside

Out of the 33 analysts that have coverage on Zydus Lifesciences, 17 of them have a “buy” rating, 10 say “hold”, while six of them have a “sell” rating on the stock.

Leave a Reply

Your email address will not be published. Required fields are marked *